EGFR and neoplasm: In almost all samples derived from different EGFR inhibitor resistant tumors, protein levels of phospho-MAPK were low, with the exception of the one tumor resistant to gefitinib-afatinib-osimertinib, in which we detected the KRAS-G12D mutation (Figures 5A, 7A).